Phase I/II Trial of Radiation Therapy Plus Temozolomide With MK-3475 in Patients With Newly Diagnosed Glioblastoma (GBM)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Nov 2020.
- 10 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 10 Jun 2017 Biomarkers information updated